A critique of Women's Health Initiative Studies (2002-2006).

The Women's Health Initiative Studies (WHI) were designed to examine the effects of estrogen and progestin (E+P; Prempro) and estrogen alone (Premarin) in post-menopausal women. The authors of the WHI studies and the National Heart Lung and Blood Institute (NHLBI) concluded that E+P treatment increased the risks of coronary heart disease, invasive breast cancer, stroke and venous thromboembolism. The following paper contains a reevaluation of these studies based on the graphic analysis of their tabulated data. In contrast to the conclusions reached by the WHI and the NHLBI, I conclude that treatment of post-menopausal women with estrogen and progestin (Prempro) does not increase the risks of cardiovascular disease, invasive breast cancer, stroke or venous thromboembolism. I also disagree with the claim that an increased risk of stroke existed in women treated with estrogen alone.